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The composition of the tumor microenvironment is
associated with a patient's prognosis and can be
therapeutically targeted. A link between the cellular
composition and genomic features of the tumor and
its response to immunotherapy is beginning to
emerge. Analyzing the microenvironment of tumor
molecular subgroups can be a useful approach to
tailor immunotherapies.immune destruction, either by expressing inhibitory li-The importance of the immune microenvironment
Cancer cells grow within a microenvironment where
they interact with stromal cells (such as fibroblasts and
endothelial cells) and immune cells. These interactions
are of prime relevance for the outcome of patients with
cancer. Our understanding of how the adaptive immune
system controls tumor growth and metastatic spread has
vastly improved in the past decade. An early example of
these studies in colorectal cancer (CRC) showed that
high densities of memory and cytotoxic T cells are asso-
ciated with favorable patient prognosis, a result that has
since been extended to a large number of other cancers
[1]. Other adaptive immune cells were reported to be
implicated in this anti-tumor mechanism, notably type
1 T helper (Th1) lymphocytes, which activate cytotoxic
T cells, and B cells, which can produce tumor-targeting
antibodies [1]. Lymphocytes form aggregates surround-
ing the tumor, an observation that was first made in
non-small cell lung cancer, and these aggregates can be
organized in tertiary lymphoid structures that structur-
ally resemble secondary lymphoid organs (lymph nodes)
where systemic immune responses are mounted. These
structures seem to locally foster Th1/CD8 immune* Correspondence: herve.fridman@crc.jussieu.fr
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mature dendritic cells (mDCs) [2].
These findings have since been translated into the
clinic, with agents that stimulate the activity of cytotoxic
T cells, such as immune checkpoint inhibitors, yielding
clinical responses in patients with advanced-stage can-
cer. Immune checkpoints mostly consist of T-cell-
expressed receptors (such as CTLA4 or PD-1), whose
binding to ligands (such as PD-L1) suppresses T-cell ac-
tivity. Tumor cells can coopt this mechanism to evade
gands themselves or by recruiting myeloid cells or other
immune subsets that express these ligands. Anti-
checkpoint treatments, such as antibodies that block
these receptors or ligands, interfere with immunosup-
pressive signals to restore the anti-tumor potential of
cytotoxic cells. These treatments elicit up to 30 % of ob-
jective responses in metastatic cancers [3], with the re-
sponse rate depending on tumor type. It is of paramount
importance to develop tumor classification systems able
to predict responders to these treatments.
Pro-tumorigenic inflammation, another immune-
mediated effect, has also been documented [4]. Inflamma-
tion signals mobilize the immune system in response to
perturbations of tissue homeostasis, such as wounding or
infection. Tumors can subvert inflammatory signals to
sustain carcinogenesis by the production of mutagens,
growth signals and angiogenic molecules, or by activation
of matrix remodeling pathways [4]. Inflammation seems
to have a role in the suppression of adaptive anti-tumor
immune responses through stimulation of the production
of regulatory T cells and suppressive myeloid cells, as well
as the production of soluble immunosuppressive factors
such as TGFß. Future successful immunotherapeutic ap-
proaches will be likely to aim at simultaneously restoring
the adaptive immune response while decreasing the pro-
tumorigenic inflammation. Understanding the immune
microenvironment of tumors is therefore important in the
development of tailored immunotherapies.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Becht et al. Genome Medicine  (2015) 7:115 Page 2 of 3Integrating immune and molecular classification
of tumors
Prediction of response to immunotherapies has been a
major goal in studies of the immune microenvironment.
Our group characterized the immune microenvironment
of pulmonary metastases from CRC and clear-cell renal
cell carcinoma (ccRCC) [5]. This analysis revealed that,
within the same surrounding pulmonary tissue, the
immune cell densities found in the tumor microenviron-
ment, as well as their associated prognostic values, are
influenced by the metastasis-forming malignant cell(s).
This finding suggests a critical role of these metastasis-
forming malignant cells in shaping the tumor’s immune
microenvironment. Therefore, we would expect to see a
correlation between the molecular signature of a tumor
cell and its immunological features.
Several types of cancer have now been divided into
molecularly homogeneous subgroups, which are usually
established using unsupervised classification of 'omics'
data. These molecular signatures are often associated
with genomic features of the tumors and clinical charac-
teristics of the patients. To analyze the relationship be-
tween the immune microenvironment and molecular
subgroups of various cancers, we developed a method to
identify and measure the expression of genes specific to
the main immune and stromal cell populations.
This method was first applied in a cohort of primary
tumors from metastatic ccRCC, in which four molecular
subgroups were identified [6]. This analysis revealed a
significant association between ccRCC molecular sub-
groups and immune infiltrates. In particular, it revealed
that a sunitinib-resistant subgroup with significantly
shorter overall survival is highly infiltrated by cytotoxic
T cells and expresses genes related to a Th1 functional
orientation, as well as being highly infiltrated by cells of
monocytic origin (macrophages) and expressing high
levels of inflammatory, immunosuppressive and check-
point molecules (PD-1 and its ligands and LAG3) [6, 7].
These observations indicate the presence of a highly
inflammatory microenvironment in which anti-tumor
effector cells are present but their activity is suppressed.
The presence of effector cells in conjunction with the
expression of checkpoint molecules suggests that the
ccrcc4 molecular subgroup could be enriched for re-
sponders to inhibitors of the PD-1 pathway.
Many independent teams have proposed molecular
classifications of CRC in the past few years. They all
agree on the identification of a microsatellite-instable
(MSI)-enriched subgroup associated with favorable prog-
nosis, and a mesenchymal subgroup associated with poor
prognosis [8]. Analysis of the immune microenvironment
of molecularly classified CRC tumors strikingly revealed
that these two subgroups with opposed prognosis are
both highly infiltrated by immune cells [7]. The previouslydescribed immunological subgroup of CRC that was
marked by extensive infiltration by cytotoxic T cells,
with high expression of genes encoding memory T-cell
chemoattractants or cytokines promoting cytotoxic T-
cell-mediated immunity, closely corresponded to the
MSI-enriched subgroup, whose genome is notable for
its high mutational burden due to defects in the DNA
repair machinery. This subgroup also had the highest
expression of checkpoint molecules, such as PD-L1 and
PD-L2, among all CRC subgroups studied, which suggests
it could respond to anti-PD-1 treatments [7]. Subsequent
reports confirmed this hypothesis, as MSI enrichment
seems to be tightly correlated to response to pembrolizu-
mab, a PD-1-targeting monoclonal antibody [9]. Strik-
ingly, another report showed that in non-small cell lung
cancer, the overall mutational load of the tumors is associ-
ated with response to PD-1 blockade [10]. Therefore, anti-
genicity (the capacity to elicit an adaptive immune
response), which is tightly associated with the presence of
DNA-encoded non-synonymous mutations, as well as
with a cytotoxic orientation of the microenvironment,
could be a major determinant of response to checkpoint
inhibitors.
Combination of immunotherapies or drugs targeting
other features of the tumor microenvironment might,
however, benefit other subgroups of patients. The analysis
of CRC molecular subgroups also revealed a previously
unidentified 'immune-high' subgroup of CRC [7]: the
poor-prognosis mesenchymal subgroup indeed expressed
intermediate levels of markers of the adaptive immune re-
sponse and checkpoint molecules, in conjunction with a
high degree of infiltration by macrophages, high expres-
sion of inflammatory genes, high degree of angiogenesis
and fibroblast infiltration, and abundance of soluble
immunosuppressive molecules such as TGFß [7]. This
pattern suggests that, similarly to the situation in poor-
prognosis ccRCC tumors, high inflammation hampers the
activity of cytotoxic cells in mesenchymal CRC tumors,
and thus anti-inflammatory or anti-angiogenic treatments
could be used in combination with checkpoint inhibitors
to simultaneously dampen inflammatory signals and re-
store cytotoxic T-cell function in this subgroup.
Altogether, these data, which will be extended to
other cancers, illustrate that molecular genome-wide
and immune classifications of tumors are highly corre-
lated, and that together they enable the discovery of
different immune microenvironments within a given can-
cer that can be therapeutically targeted.
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